Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma By Ogkologos - July 2, 2025 349 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DESTINY-Gastric04 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Incidence of Colorectal, Breast, Kidney, Pancreatic, and Uterine Cancers is Increasing... May 18, 2022 Lighting Ceremony at Lincoln Memorial Honors the 400,000 Lives Lost to... January 20, 2021 FDA Approves Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn for Acute Lymphoblastic Leukaemia and... July 13, 2021 Zenocutuzumab Shows Efficacy in Patients with Advanced NRG1 Fusion-positive Cancers February 19, 2025 Load more HOT NEWS Overcoming a Cancer Nemesis? KRAS Inhibitor Shows Promise in Early Trial Study Shows Music Eases Pain and Other Symptoms for Patients Undergoing... Can Acupuncture Help Cancer Survivors with Chronic Pain? Breast Cancer Patient Devotes Her Time to Driving Others to Treatment
